Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in
patients with moderate to severe ulcerative colitis over 28 days. This trial will also
explore pharmacokinetics (PK) profile and preliminary therapeutic efficacy associated with
OST-122 through biomarker analysis and clinical, endoscopic and histologic assessments.